Drugmakers are actively presenting their visions for the future of obesity treatments at the American Diabetes Association's Scientific Sessions. Eli Lilly and Novo Nordisk are currently the market leaders, with Lilly showcasing impressive data from its experimental triple-acting drug retatrutide, which has demonstrated significant weight loss results.
Novo Nordisk reported that its Wegovy pill has already surpassed 3 million prescriptions within five months of launch, indicating strong demand for oral weight-loss options. New entrants like Structure Therapeutics and AstraZeneca are also making strides, with potential products expected to hit the market by 2029.
Pfizer is developing a monthly injection, which could offer more convenience than current weekly options, while Amgen is exploring treatments that could be administered quarterly. Zealand Pharma is investigating amylin-based drugs, which may provide a better patient experience.
Analysts are closely watching whether the market will remain dominated by Lilly and Novo or if new competitors will emerge as significant players. Pricing strategies are a key concern, especially as both Lilly and Novo have reduced their drug prices in response to competition.
With obesity affecting billions globally, the evolving landscape of obesity treatments could lead to more accessible and effective options for patients in the future